5-MeO-ñET, also known as 5-methoxy-ñ-ethyltryptamine, is a psychoactive drug of the tryptamine and ñ-alkyltryptamine families. It reportedly produces psychedelic and stimulant effects.
The dose range of 5-MeO-ñET is 50 to 75mg orally. 5-MeO-ñET produces entactogenic and stimulant effects that can last 4 to 6hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dose and effects can be expected.
The pharmacology of 5-MeO-ñET has been studied. It is a weak partial agonist of the serotonin 5-HT<sub>2A</sub> receptor, with a binding affinity (K<sub>i</sub>) of 4,073nM, an of 166nM, and an of 34%. For comparison, ñET showed 14-fold lower affinity for the receptor than 5-MeO-ñET and was inactive as an agonist of the receptor. The individual stereoisomers of 5-MeO-ñET and ñET were also assessed.
Analogues of 5-MeO-AET include ñ-ethyltryptamine (AET), ñ-methylserotonin (5-HO-AMT), 5-MeO-AMT, 4-methyl-AET, 5-fluoro-AET, 5-EtO-AMT, 5-fluoro-AET, 5-chloro-AET, and 7-methyl-AET, among others.
5-MeO-AET is not a controlled substance in Canada as of 2025.
5-MeO-ñET is unscheduled and uncontrolled in the United States, but possession and sales of 5-MeO-ñET could be prosecuted under the Federal Analog Act because of its structural similarities to ñET and ñMT.